Endosc Int Open 2014; 02(04): E256-E258
DOI: 10.1055/s-0034-1377612
Case report
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic ultrasound-guided ethanol ablation of a large metastatic carcinoid tumor: success with a note of caution

Bradley W. Mathers
1   Penn State Hershey Medical Center – Internal Medicine, Hershey, Pennsylvania, United States
,
Harold A. Harvey
2   Penn State Hershey Medical Center – Hematology and Oncology, Hershey, Pennsylvania, United States
,
Charles E. Dye
3   Penn State Hershey Medical Center – Gastroenterology and Hepatology, Hershey, Pennsylvania, United States
,
Brandy Dougherty-Hamod
3   Penn State Hershey Medical Center – Gastroenterology and Hepatology, Hershey, Pennsylvania, United States
,
Matthew T. Moyer
3   Penn State Hershey Medical Center – Gastroenterology and Hepatology, Hershey, Pennsylvania, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 11. März 2014

accepted after revision 23. Juni 2014

Publikationsdatum:
19. September 2014 (online)

Endoscopic ultrasonography with fine needle infusion (EUS-FNI) of alcohol is the most reported method for EUS-guided tumor ablation. Several studies have reported successful EUS-guided ablation of pancreatic neuroendocrine tumors. However, these tumors have been relatively small (< 3 cm). In this report, a 50-year-old man with a metastatic carcinoid tumor with a large porta hepatis mass was referred to our clinic for EUS-guided ethanol ablation. After two separate EUS-FNI ablations, there was a 36 % reduction in tumor size (9.0 × 11.4 cm to 6.7 × 9.8 cm) with associated tumor lysis syndrome. Chromogranin A levels decreased from 460 to 132 ng/mL. The patient reported complete resolution of abdominal pain within 2 weeks, but only mild improvement in flushing and diarrhea. In conclusion, large metastatic neuroendocrine tumors can be successfully treated with EUS-guided ethanol ablation. Evidence-based guidelines are needed with regard to the appropriate volume of ethanol injected in EUS-guided ablation to promote the efficacy and safety of this emerging procedure.